Biogen Leverages Strength In MS Treatments

By the end of the third quarter, Biogen's multiple sclerosis treatments Avonex, Tysabri, and Tecfidera had racked up $3.94 billion in sales so far for the year — about 80% of total revenue.
READ MORE